ArticleCancer imaging : the official publication of the International Cancer Imaging Society2020
iRECIST: how to do it.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07174453 (A Late Phase Randomized Open-Label Multi Cohort Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Late Phase Randomized Open-Label Multi Cohort Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features.Cancer immunology, immunotherapy : CII · 2026Pooled it
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021Trial
- Radiotherapy-induced abscopal effects in immune checkpoint inhibitor-refractory metastatic disease: results from a large multicenter real-world cohort study.Oncoimmunology · 2026Article
- Radiotherapy in patients with NSCLC developing progressive disease during immune checkpoint inhibition: Abscopal responses and survival.Clinical and translational radiation oncology · 2026Article
- Utility of iRECIST for evaluating treatment efficacy in patients receiving immune checkpoint inhibitors.Journal of gynecologic oncology · 2026Article
- Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.Annals of gastroenterological surgery · 2026Review
- IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Medical imaging in immunotherapy response evaluation: from RECIST to AI-driven longitudinal models, and the distinction between risk prediction and kinetic diagnosis.Frontiers in medicine · 2026Review
- Global and regional accuracy of deep learning-based tumor segmentation from whole-body [EJNMMI research · 2025Article
- The Role of 18F-FDG PET/CT in Monitoring Immunotherapy Response in Non-Small Cell Lung Cancer: Current Evidence and Challenges: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Abscopal effects in patients with malignant melanoma treated with radiotherapy and immune checkpoint inhibition: analysis of a large observational multicenter study.Journal for immunotherapy of cancer · 2025Observational
- The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy.Clinical & experimental metastasis · 2025Article
- Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients.European radiology · 2025Article
- The impact of β-blockers on outcomes of immune checkpoint inhibitors therapy in advanced lung cancer: a multicenter real-world study.Frontiers in immunology · 2025Article
- Sex-specific differences in abscopal responses to combined radiotherapy and immune checkpoint inhibition-insights from a multicenter study.Frontiers in immunology · 2025Observational
- Imaging patterns and recommendations for diagnosis, staging, and management of lung cancer.BJR open · 2025Review
- High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades.European radiology experimental · 2024Article
- Immune-related adverse events of antibody-based biological medicines in cancer therapy.Journal of cellular and molecular medicine · 2024Review
- Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundiRECIST for the objective monitoring of immunotherapies was published by the official RECIST working group in 2017. MAIN BODY: Immune-checkpoint inhibitors represent one of the most important therapy advancements in modern oncology. They are currently used for treatment of multiple malignant diseases especially at advanced, metastatic stages which were poorly therapeutically accessible in the past. Promising results of recent studies suggest that their application will further grow in the near future, particularly when used in combination with chemotherapy. A challenging aspect of these immunotherapies is that they may show atypical therapy response patterns such as pseudoprogression and demonstrate a different imaging spectrum of adverse reactions, both of which are crucial for radiologists to understand. In 2017 the RECIST working group published a modified set of response criteria, iRECIST, for immunotherapy, based on RECIST 1.1 which was developed for cytotoxic therapies and adapted for targeted agents.
conclusionThis article provides guidance for response assessment of oncologic patients under immunotherapy based on iRECIST criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.